Tg Therapeutics (TGTX) Shares Outstanding (Weighted Average) (2011 - 2026)

Tg Therapeutics' Shares Outstanding (Weighted Average) history runs 16 years deep, the most recent figure standing at $144.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) fell 1.53% year-over-year to $144.4 million; the TTM figure through Mar 2026 stood at $144.4 million (down 1.53% YoY), while the FY2025 annual figure was $144.3 million, down 0.69% from the prior year.
• Shares Outstanding (Weighted Average) was $144.4 million for Q1 2026 at Tg Therapeutics, roughly flat from $144.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $146.7 million in Q2 2025 to a low of $134.4 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $142.0 million across 5 years, with a median of $144.3 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Weighted Average) increased 5.57% in 2023, then fell 1.53% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $135.4 million in 2022, then gained by 4.83% to $142.0 million in 2023, then advanced by 2.37% to $145.3 million in 2024, then declined by 0.69% to $144.3 million in 2025, then grew by 0.08% to $144.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $144.4 million (Q1 2026), $144.3 million (Q4 2025), and $145.4 million (Q3 2025), per Business Quant data.